ASND – Ascendis Pharma A/S
ASND — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.23
Margin Of Safety %
-42
Put/Call OI Ratio
0.26
EPS Next Q Diff
EPS Last/This Y
15.72
EPS This/Next Y
-2.01
Price
263.67
Target Price
289.64
Analyst Recom
1.1
Performance Q
21.55
Upside
-56.3%
Beta
0.34
Ticker: ASND
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-06-02 | ASND | 216.48 | 0.97 | 0.71 | 9860 |
| 2026-06-03 | ASND | 217.06 | 0.96 | 0.16 | 9937 |
| 2026-06-04 | ASND | 218.76 | 0.95 | 0.01 | 9992 |
| 2026-06-05 | ASND | 210.39 | 0.49 | 0.33 | 15097 |
| 2026-06-08 | ASND | 205.78 | 0.49 | 0.21 | 15104 |
| 2026-06-09 | ASND | 213.14 | 0.47 | 7.06 | 15066 |
| 2026-06-10 | ASND | 209.98 | 0.49 | 0.17 | 15305 |
| 2026-06-11 | ASND | 215.61 | 0.49 | 10.05 | 15319 |
| 2026-06-12 | ASND | 218.54 | 0.42 | 0.07 | 14751 |
| 2026-06-15 | ASND | 223.41 | 0.42 | 0.00 | 14752 |
| 2026-06-16 | ASND | 230.93 | 0.41 | 0.31 | 14813 |
| 2026-06-17 | ASND | 231.15 | 0.41 | 6.78 | 14974 |
| 2026-06-18 | ASND | 230.58 | 0.36 | 0.01 | 14643 |
| 2026-06-22 | ASND | 228.22 | 0.22 | 0.06 | 10389 |
| 2026-06-23 | ASND | 238.5 | 0.22 | 0.00 | 10582 |
| 2026-06-24 | ASND | 237.76 | 0.42 | 0.07 | 6585 |
| 2026-06-25 | ASND | 261.24 | 0.39 | 0.15 | 6916 |
| 2026-06-26 | ASND | 260.75 | 0.32 | 0.05 | 8516 |
| 2026-06-29 | ASND | 263.83 | 0.26 | 0.31 | 11385 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-06-01 | ASND | 218.60 | - | - | 11.44 |
| 2026-06-02 | ASND | 216.81 | - | - | 11.44 |
| 2026-06-03 | ASND | 216.85 | - | - | 11.44 |
| 2026-06-04 | ASND | 218.82 | - | - | 11.44 |
| 2026-06-05 | ASND | 210.29 | - | - | 11.44 |
| 2026-06-08 | ASND | 205.78 | - | - | 11.44 |
| 2026-06-09 | ASND | 213.18 | - | - | 11.44 |
| 2026-06-10 | ASND | 209.77 | - | - | 11.44 |
| 2026-06-11 | ASND | 215.32 | - | - | 11.44 |
| 2026-06-12 | ASND | 218.02 | - | - | 11.44 |
| 2026-06-15 | ASND | 223.50 | - | - | 11.44 |
| 2026-06-16 | ASND | 231.05 | - | - | 11.44 |
| 2026-06-17 | ASND | 230.82 | - | - | 11.44 |
| 2026-06-18 | ASND | 230.78 | - | - | 11.44 |
| 2026-06-22 | ASND | 228.10 | - | - | 11.45 |
| 2026-06-23 | ASND | 238.59 | - | - | 11.45 |
| 2026-06-24 | ASND | 237.95 | - | - | 11.45 |
| 2026-06-25 | ASND | 261.30 | - | - | 11.45 |
| 2026-06-26 | ASND | 261.17 | - | - | 11.45 |
| 2026-06-29 | ASND | 263.67 | - | - | 11.45 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-06-02 | ASND | -3.21 | -45.97 | 2.80 |
| 2026-06-03 | ASND | -3.19 | -45.97 | 2.80 |
| 2026-06-04 | ASND | -3.19 | -45.97 | 2.80 |
| 2026-06-05 | ASND | -3.19 | -45.97 | 2.80 |
| 2026-06-08 | ASND | -3.19 | -45.17 | 2.80 |
| 2026-06-09 | ASND | -3.19 | -45.17 | 2.80 |
| 2026-06-10 | ASND | -3.19 | -45.17 | 2.79 |
| 2026-06-11 | ASND | -3.19 | -45.17 | 2.79 |
| 2026-06-12 | ASND | -3.19 | -45.17 | 2.79 |
| 2026-06-15 | ASND | -3.19 | -45.14 | 2.79 |
| 2026-06-16 | ASND | -3.19 | -45.14 | 2.79 |
| 2026-06-17 | ASND | -3.19 | -45.14 | 2.79 |
| 2026-06-18 | ASND | -3.19 | -45.14 | 2.79 |
| 2026-06-22 | ASND | -3.19 | -44.75 | 2.79 |
| 2026-06-23 | ASND | -3.19 | -44.75 | 2.79 |
| 2026-06-24 | ASND | -3.19 | -44.75 | 2.79 |
| 2026-06-25 | ASND | -3.19 | -44.75 | 2.79 |
| 2026-06-26 | ASND | -3.19 | -44.75 | 3.23 |
| 2026-06-29 | ASND | -3.19 | -44.74 | 3.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.7
Avg. EPS Est. Next Quarter
1.15
Insider Transactions
-3.19
Institutional Transactions
-44.74
Beta
0.34
Average Sales Estimate Current Quarter
331
Average Sales Estimate Next Quarter
354
Fair Value
153.6
Quality Score
94
Growth Score
Sentiment Score
95
Actual DrawDown %
3
Max Drawdown 5-Year %
Target Price
289.64
P/E
29.72
Forward P/E
24.56
PEG
P/S
16.29
P/B
29.13
P/Free Cash Flow
323.88
EPS
8.87
Average EPS Est. Cur. Y
11.45
EPS Next Y. (Est.)
9.43
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
57.88
Relative Volume
1.17
Return on Equity vs Sector %
74
Return on Equity vs Industry %
90.8
EPS 1 7Days Diff
EPS 1 30Days Diff
1.61
EBIT Estimation
◆
ASND
Healthcare
$263.70
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
71.7
Range 1M
85.7%
Sup Dist
3.2%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
455.5%
EPS NY
-29.5%
52W%
91.2%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-37.3% upside
Upside
-37.3%
Quality
94
MoS
-42%
ASND — P/E HistoricalBiotechnology
Ascendis Pharma A/SSector: Healthcare
Industry: Biotechnology
Employees: 1189
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
ASND
Latest News
—
Caricamento notizie per ASND…
stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today
news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance
stock history ASND – Ascendis Pharma A/S invest stock market
stock prices ASND premarket after hours
ticker ASND fair value insiders trading